Terms: = Head and neck cancer AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC AND Clinical Outcome
5 results:
1. MMR markers correlate with clinical outcome in patients with esophageal squamous cell carcinoma.
Yamauchi T; Fujishima F; Tsunokake J; Kunimitsu A; Akaishi R; Ozawa Y; Fukutomi T; Okamoto H; Sato C; Taniyama Y; Kamei T; Ichinohasama R; Sasano H
Int J Biol Markers; 2023 Jun; 38(2):105-113. PubMed ID: 37009661
[TBL] [Abstract] [Full Text] [Related]
2. Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas.
Wong KS; Lorch JH; Alexander EK; Nehs MA; Nowak JA; Hornick JL; Barletta JA
Thyroid; 2019 May; 29(5):666-673. PubMed ID: 30869569
[No Abstract] [Full Text] [Related]
3. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
Alexander BM; Wang XZ; Niemierko A; Weaver DT; Mak RH; Roof KS; Fidias P; Wain J; Choi NC
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):164-71. PubMed ID: 22000749
[TBL] [Abstract] [Full Text] [Related]
4. Deficiency of hmlh1 and hMSH2 expression is a poor prognostic factor in esophageal squamous cell carcinoma.
Uehara H; Miyamoto M; Kato K; Cho Y; Kurokawa T; Murakami S; Fukunaga A; Ebihara Y; Kaneko H; Hashimoto H; Murakami Y; Shichinohe T; Kawarada Y; Itoh T; Okushiba S; Kondo S; Katoh H
J Surg Oncol; 2005 Nov; 92(2):109-15. PubMed ID: 16231369
[TBL] [Abstract] [Full Text] [Related]
5. Reduced mlh1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers.
Kishi K; Doki Y; Yano M; Yasuda T; Fujiwara Y; Takiguchi S; Kim S; Higuchi I; Monden M
Clin Cancer Res; 2003 Oct; 9(12):4368-75. PubMed ID: 14555508
[TBL] [Abstract] [Full Text] [Related]
